Home  About us  Contact
 

Pediatric Oncology (pediatric + oncology)

Distribution by Scientific Domains
Medical Sciences93%

Terms modified by Pediatric Oncology

  • pediatric oncology patient
    		•

    Selected Abstracts

    The American Society of Pediatric Hematology/Oncology (ASPHO) 2010 Distinguished Career Award Goes to Dr. Sam Lux

    PEDIATRIC BLOOD & CANCER, Issue 6 2010
    David A. Williams MD
    No abstract is available for this article. [source]

    The American Society of Pediatric Hematology/Oncology (ASPHO) 2006 distinguished career award goes to W. Archie Bleyer, MD

    PEDIATRIC BLOOD & CANCER, Issue 6 2006
    F. Leonard Johnson MD
    No abstract is available for this article. [source]

    42nd Congress of the International Society of Pediatric Oncology (SIOP) in Boston: A tribute to the two pioneers in pediatric oncology

    PEDIATRIC BLOOD & CANCER, Issue 5 2010
    Katrin Scheinemann MD
    No abstract is available for this article. [source]

    Preoperative Wilms tumor rupture

    CANCER, Issue 1 2008
    A retrospective study of 57 patients
    Abstract BACKGROUND. According to current International Society of Pediatric Oncology (SIOP) Wilms recommendations, all preoperative tumor ruptures should be classified as stage IIIc. However, to the authors' knowledge, the definition and diagnostic criteria of preoperative rupture have not been defined clearly. METHODS. The authors performed a retrospective analysis of 57 children with clinical and/or radiologic (computed tomography [CT]) signs of preoperative tumor rupture of a series of 250 patients enrolled in Wilms SIOP protocols at their institution. RESULTS. Clinical and radiologic signs of preoperative rupture were observed in 39 patients and 55 patients, respectively. The site of rupture on imaging was retroperitoneal only in 48 patients and both retroperitoneal and intraperitoneal in 7 patients. Surgery was performed after chemotherapy in 55 of 57 patients. Peritoneal disease recurrence occurred in 3 of 57 patients, including 2 patients with stage III tumors who had initial intraperitoneal rupture and 1 patient with a stage I tumor. Among the 48 patients who had radiologic signs of retroperitoneal-only rupture, the final pathologic stage was stage III in 22 patients, stage II in 9 patients, and stage I in 17 patients, and no abdominal disease recurrence was observed, although only 23 of 48 patients received flank radiotherapy. The 5-year local control rate was significantly higher in patients who had retroperitoneal-only rupture compared with patients who had intraperitoneal rupture (100% vs 83.3%; standard error, ±15.2%; P = .0015). CONCLUSIONS. The use of CT scans significantly increased the number of patients who could be classified with "tumor rupture." Intraperitoneal rupture was diagnosed accurately with CT and was associated with a significant risk of peritoneal disease recurrence. In contrast, patients who have radiologic signs of localized retroperitoneal-only rupture at diagnosis most likely should not be upstaged, and their treatment may be determined according to pathologic stage only. Cancer 2008. © 2008 American Cancer Society. [source]

    Preradiation chemotherapy for pediatric patients with high-grade glioma,

    CANCER, Issue 1 2002
    Dr. med. habil, Johannes E. A. Wolff M.D.
    Abstract BACKGROUND To evaluate the feasibility and efficacy of intensive chemotherapy given prior to irradiation in pediatric patients with malignant glioma, the Society of Pediatric Oncology in Germany started a randomized trial in 1991. The high-grade glioma strata had to be closed because of insufficient patient accrual. The follow-up data from these patients are reported. METHODS Fifty-two patients with World Health Organization (WHO) Grade 4 malignant glioma (n = 27 patients) or with WHO Grade 3 anaplastic astrocytoma (n = 25 patients) between the ages of 3 years and 17 years were available for analysis. The tumor locations were supratentorial in 42 patients, the cerebellum in 8 patients, and the spinal cord in 2 patients (the brainstem was excluded). Tumor surgeries were biopsy in 10 patients, partial resection in 5 patients, subtotal resection in 10 patients, and macroscopic total resection in 21 patients. Patients received either 54 grays of irradiation (n = 22 patients) followed by chemotherapy with lomustine, vincristine, and cisplatin (maintenance chemotherapy) or sandwich chemotherapy (n = 30 patients), which consisted of ifosfamide, etoposide, methotrexate, cisplatin, and cytosine arabinoside followed by irradiation. RESULTS The extent of resection was the most important prognostic factor. The median survival was 5.2 years for patients who underwent tumor resection of , 90% compared with 1.3 years for patients who underwent less than complete resection (P < 0.0005). After undergoing macroscopic total resection, sandwich chemotherapy (n = 15 patients) resulted in better overall survival (median, 5.2 years) compared with the maintenance protocol (n = 16 patients; median survival, 1.9 years; P = 0.015). A Cox multivariate regression analysis showed better survival for female patients (P = 0.025), WHO Grade 3 disease (P = 0.016), tumor resection of , 90% (P = 0.003), irradiation with , 54 grays (P = 0.003), and sandwich chemotherapy (P = 0.006). CONCLUSIONS These data suggest that early, intensive chemotherapy increases survival rates in patients with malignant glioma who undergo complete resection. Cancer 2002;94:264,71. © 2002 American Cancer Society. [source]

    Pediatric oncology in Norway

    PEDIATRIC BLOOD & CANCER, Issue 4 2004
    Arty R. Coppes-Zantinga MA
    No abstract is available for this article. [source]

    Neurocognitive effects of treatment for childhood cancer

    DEVELOPMENTAL DISABILITIES RESEARCH REVIEW, Issue 3 2006
    Robert W. Butler
    Abstract We review research on the neuropsychological effects that central nervous system (CNS) cancer treatments have on the cognitive abilities of children and adolescents. The authors focus on the two most common malignancies of childhood: leukemias and brain tumors. The literature review is structured so as to separate out earlier studies, generally those published prior to 1995, as opposed to manuscripts that have been published within the past decade. This is an important distinction for both leukemia and brain tumors. Earlier studies were ground breaking in that they began to map out what could be expected in terms of intelligence and academic problems in survivors of pediatric malignancies. Survivorship in this population has and continues to markedly increase and this is largely due to changes in treatment protocols. Research on neurocognitive effects of disease and treatment in pediatric oncology has become increasingly sophisticated, and this literature review not only reflects this trend, but highlights the growing collaboration between neuropsychology, cognitive neuroscience, and neuro-imaging. Thus, our goal was to provide a historical foundation, lead the reader towards the progression of research methodology up to the current state of the art, and perhaps most importantly, discuss future directions. These directions are especially relevant to the concepts of remediation and treatment of cognitive problems, and this is emphasized at the conclusion of the review. MRDD Research Reviews 2006;12:184,191. © 2006 Wiley-Liss, Inc. [source]

    Extremity salvage with a free musculocutaneous latissimus dorsi flap and free tendon transfer after resection of a large congenital fibro sarcoma in a 15-week-old infant.

    MICROSURGERY, Issue 6 2006
    A case report
    A case of complex microsurgical reconstruction of the dorsum of the foot, including tendon transfer following tumor resection, in a 15-week-old male infant is presented. After birth, a 5.5 × 4 cm large tumor was observed on the dorsum of the right foot. Biopsy showed a congenital malignant fibro sarcoma. After initial chemotherapy a radical excision of the tumor at the age of 14 weeks was followed. To cover the defect a musculocutaneous latissimus dorsi flap was taken, the cutaneous part being large enough to cover the defect. Extensor tendons were reconstructed with free tendon transplants. Amputation is usually indicated in these cases. To the best of our knowledge, microsurgical reconstruction in infants at this age with congenital malignant tumors has not yet been reported. The case shows that Plastic surgery can play an important role in pediatric oncology and should routinely be integrated into the multi-modal treatment concepts. © 2006 Wiley-Liss, Inc. Microsurgery, 2006. [source]

    42nd Congress of the International Society of Pediatric Oncology (SIOP) in Boston: A tribute to the two pioneers in pediatric oncology

    PEDIATRIC BLOOD & CANCER, Issue 5 2010
    Katrin Scheinemann MD
    No abstract is available for this article. [source]

    Antidepressants in pediatric oncology

    PEDIATRIC BLOOD & CANCER, Issue 6 2008
    Carlo Alfredo Clerici MD
    No abstract is available for this article. [source]

    Antidepressants in pediatric oncology: Response

    PEDIATRIC BLOOD & CANCER, Issue 6 2008
    Leslie S. Kersun MD
    No abstract is available for this article. [source]

    A brief history of pediatric oncology in Porto, Portugal

    PEDIATRIC BLOOD & CANCER, Issue 4 2002
    B.P. Sodré Borges MD
    No abstract is available for this article. [source]

    Recombinant human erythropoietin in pediatric oncology: A review,

    PEDIATRIC BLOOD & CANCER, Issue 4 2002
    James Feusner MD
    Abstract Background Numerous reports on recombinant human erythropoietin (rHuEPO, epoetin alfa) treatment of cancer-related anemia in adult patients have been published to date. These have shown that epoetin increases hemoglobin levels, significantly ameliorates symptoms of anemia, and improves adult patients' quality of life. Unfortunately, less is known about the impact of epoetin on anemia in pediatric cancer patients. Procedure It is the objective of this review to summarize and analyze data of clinical trials of epoetin treatment of anemia in pediatric cancer patients. Results A total of 15 studies were reviewed; eight were considered for detailed analysis and demonstrated important variabilities in study methods. Four of the eight were controlled, randomized trials and four were open label. Conclusions These studies suggested an overall beneficial effect of epoetin alfa for treating anemia in children with cancer. Three large, multicenter clinical trials of the efficacy and safety of epoetin alfa in anemic children with cancer are currently underway, one in Europe and two in North America. Med Pediatr Oncol 2002; 39:463,468. © 2002 Wiley-Liss, Inc. [source]

    Masera G. Report of the committee on psychosocial issues of the international society of pediatric oncology (SIOP): Who can decide what is in a child's best interest?

    PEDIATRIC BLOOD & CANCER, Issue 1 2001
    A problem-solving approach.
    No abstract is available for this article. [source]

    International Classification of Childhood Cancer, third edition,,

    CANCER, Issue 7 2005
    Eva Steliarova-Foucher Ph.D.
    Abstract BACKGROUND The third edition of the International Classification of Diseases for Oncology (ICD-O-3), which was published in 2000, introduced major changes in coding and classification of neoplasms, notably for leukemias and lymphomas, which are important groups of cancer types that occur in childhood. This necessitated a third revision of the 1996 International Classification of Childhood Cancer (ICCC-3). METHODS The tumor categories for the ICCC-3 were designed to respect several principles: agreement with current international standards, integration of the entities defined by newly developed diagnostic techniques, continuity with previous childhood classifications, and exhaustiveness. RESULTS The ICCC-3 classifies tumors coded according to the ICD-O-3 into 12 main groups, which are split further into 47 subgroups. These 2 levels of the ICCC-3 allow standardized comparisons of the broad categories of childhood neoplasms in continuity with the previous classifications. The 16 most heterogeneous subgroups are broken down further into 2,11 divisions to allow study of important entities or homogeneous collections of tumors characterized at the cytogenetic or molecular level. Some divisions may be combined across the higher-level categories, such as the B-cell neoplasms within leukemias and lymphomas. CONCLUSIONS The ICCC-3 respects currently existing international standards and was designed for use in international, population-based, epidemiological studies and cancer registries. The use of an international classification system is especially important in the field of pediatric oncology, in which the low frequency of cases requires rigorous procedures to ensure data comparability. Cancer 2005. © 2005 American Cancer Society. [source]